ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements
Indrayani Biotech announced its Rights Issue of up to 3.25 crore partly paid-up equity shares at ₹15 per share, aggregating to ₹48.79 Crore.
Indrayani Biotech Ltd has revised the schedule for its rights issue. The issue will now be open from September 15, 2026, to October 14, 2026.
Indrayani Biotech Ltd announced the resignation of Mr. K. Ravichandran as its Secretarial Auditor, effective August 6, 2026. The company will appoint a successor in due course.
Indrayani Biotech received approval from the Registrar of Companies to extend the deadline for its FY 2025-26 Annual General Meeting by two months, until November 30, 2026.
Indrayani Biotech Ltd reported revenue from operations of ₹37.8 Cr (-25.3% YoY) and net profit of ₹1 Cr for Q4 FY26.
Indrayani Biotech Ltd reported revenue from operations of ₹72.8 Cr (+43.9% YoY) and net profit of ₹1.1 Cr for Q4 FY26.
Indrayani Biotech Ltd has scheduled a Board of Directors meeting for August 17, 2026, to consider and approve the audited financial results for the year ended March 31, 2026.
A quarterly shareholding pattern filing by Indrayani Biotech Ltd for the period ending June 30, 2026.
Indrayani Biotech announced that the Income Tax Appellate Tribunal quashed a prior assessment order. The matter is restored to the First Appellate Authority for fresh adjudication.
Indrayani Biotech reported a delay in submitting its FY26 audited financial results due to subsidiary consolidation and audit disruptions. The trading window remains closed for designated persons.
Mr. S. Indirakumar resigned as Whole-Time Director, alleging severe governance lapses and financial mismanagement. The resignation highlights significant internal conflict and potential regulatory risks.
Indrayani Biotech revised its Rights Issue schedule to June 25 – July 24, 2026. This administrative update adjusts the capital raising timeline for eligible equity shareholders.
Indrayani Biotech Limited's Rights Issue Committee has approved the Letter of Offer, Abridged Letter of Offer, and Composite Application Form for its proposed rights issue. This marks a key procedural milestone in the company's capital-raising process.
Indrayani Biotech Ltd has filed an appeal before the Income Tax Appellate Tribunal (ITAT) against an assessment order raising a demand of ₹13.90 Crore for AY 2023-24. The company, advised by legal counsel, expects no material adverse impact on its financial operations as the matter remains sub-judice.
Indrayani Biotech Ltd has announced the ISIN (INE007C20013) for its upcoming Rights Entitlement. The issue involves partly paid-up equity shares with a face value of Rs.10 and a paid-up value of Rs.2.50 each. This follows the board's approval on April 9, 2026, for raising capital through a rights issue.
Indrayani Biotech Limited has fixed April 28, 2026, as the record date for its ₹48.79 Crore rights issue. Eligible shareholders will receive 5 rights shares for every 7 shares held at an issue price of ₹15 per share.
Indrayani Biotech Ltd has approved a rights issue of 3,25,25,897 partly paid-up equity shares at ₹15 per share, aggregating upto ₹49.90 Crore. The record date is set for April 28, 2026, with the issue opening on May 27, 2026. The rights entitlement ratio is 5 shares for every 7 shares held.
Indrayani Biotech's board approved exploring the demerger of its food division into a separate company and constituted a 'Restructuring Committee' for evaluation. Additionally, M/S Vaithianathan & Associates was appointed as Internal Auditor for FY 2025-26 and 2026-27.
Indrayani Biotech Ltd provided a clarification to BSE regarding recent share price movements, attributing them to market reactions following intimations about a Rights Issue and a potential food business demerger. The company confirmed no undisclosed material information exists.
Indrayani Biotech Ltd's Rights Issue Committee will meet on April 9, 2026, to finalize the price, entitlement ratio, and record date for its upcoming partly paid-up Rights Issue. The committee will also appoint a monitoring agency and banker to manage the capital raise process and ensure compliance.
Indrayani Biotech Ltd has scheduled a Board Meeting on April 9, 2026, to evaluate a proposal for the demerger of one of its units into a separate entity. The move is aimed at unlocking shareholder value. The company's trading window remains closed until 48 hours after the declaration of financial results.
Indrayani Biotech Limited submitted its compliance certificate for the quarter ended March 31, 2026, as per SEBI regulations. The certificate from its RTA, MUFG Intime India, confirms that securities received for dematerialisation were processed and listed on the exchanges within prescribed timelines.